This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sartorelli, A., and Tsunamura, S. Studies on the biochemical mode of action of a cytotoxic methylhydrazine derivative, n-isopropyl-a-(2-methylhydrazino)-p-toluamide. Mol Pharmacol 2: 275, 1966.
Berneis, K., Kofler, M., Bollag, W., et al. The degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxide. Experientia 19: 132, 1963.
Kreis, W., and Yen, W. An antineoplastic 14C-labeled methylhydrazine derivative in P815 mouse leukemia. A metabolic study. Experientia 21: 284, 1965.
Kreis, W. Metabolism of an antineoplastic methylhydrazine derivative in a P815 mouse neoplasm. Cancer Res 30: 82, 1970.
Martz, G., D’Alessandri, A., Keel, H., et al. Preliminary clinical results with a new antitumor agent RO 4–6467 (NSC 77213). Cancer Chemother Rep 33: 5, 1963.
Mathe, G., Berumen, L., Schweisguth, 0., et al. Methyl- hydrazine in treatment of Hodgkin’s disease and various forms of haematosarcoma and leukemia. Lancet 2: 1077, 1963.
Brunner, K., and Young, C. A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Ann Inter Med 63: 69, 1965.
Brule, G., Schlumberger, J., and Griscelli, C. N-isopropyl- a-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC 77213) in treatment of solid tumors. Cancer Chemother Rep 44: 31, 1965.
Falkson, G., Villiers, P., and Falkson, H. N-isopropyl-a- (2-methylhydrazino)-p-toluamide hydrochloride (NSC 77213) for treatment of cancer patients. Cancer Chemother Rep 46: 7, 1965.
Hope-Stone, H. Ibenzmethyzin in the treatment of the retículoses. In “Natulan (Ibenzmethyzin)”, (Jelliffe, A., and Marks, J., eds.), John Wright and Sons Ltd., pp 15–19, 1965.
Todd, I. Further experience with ibenzmethyzin. In “Natulan (Ibenzmethyzin)”, (Jelliffe, A., and Marks, J., eds.), John Wright and Sons Ltd., pp 20–25, 1965.
Dawson, W. Ibenzmethyzin in the management of late Hodgkin’s disease. In “Natulan (Ibenzmethyzin)”, (Jelliffe, A., and Marks, J., eds.), John Wright and Sons Ltd., pp 31–34, 1965.
Jelliffe, A., Bleehen, N., and Fenner, M. Short report. In “Natulan (Ibenzmethyzin)”, (Jelliffe, A., and Marks, J., eds.), John Wright and Sons Ltd., pp 35–39, 1965.
Jelliffe, A., Bleehen, N., and Fenner, M. Ibenzmethyzin in the treatment of solid tumors. In “Natulan (Ibenzmethyzin),” (Jelliffe, A., and Marks, J., eds.), John Wright and Sons Ltd., pp 53–55, 1965.
Backhouse, T., and Sicher, K. Initial experiences with methylhydrazine, a new cytotoxic agent. Clin Radiol 17: 132, 1966.
Hansen, M., Hertz, H., and Videback, A. Use of a methyl hydrazine derivative (Natulan), especially in Hodgkin’s disease. Acta Med Scand 180: 211, 1966.
Kenis, Y., DeSmedt, J., and Tagnon, H. Action de Natulan dans 94 cas de tumeurs solides. Europ J Cancer 2: 51, 1966.
Spies, S., and Snyman, H. Procarbazine (Natulan) in the treatment of Hodgkin’s disease and other lymphomas. S Afric Med J 40: 1061, 1966.
Fairley, G., Patterson, M., and Scott, R. Chemotherapy of Hodgkin’s disease with cyclophosphamide, vinblastine, and procarbazine. Brit Med J 2: 75, 1966.
DeVita, V., Serpick, A., and Carbone, P. Preliminary clinical studies with ibenzmethyzin. Clin Pharm Ther 7: 542, 1966.
Samuels, M., Leary, W., Alexanian, R., et al. Clinical trials with n-isopropyl-a-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia. Cancer 20: 1187, 1967.
Holton, C., and Selawry, 0. Clinical study of procarbazine hydrochloride in children with cancer. South Med J 60: 1375, 1967.
Bousser, J. Essai de traitement du myelome multiple par une methylhydrazine. Europ J Cancer 3: 437, 1967.
Brouet, D., Flamant, R., and Hayat, M. Results of a trial of a methylhydrazine in the treatment of epidermoid and anaplastic lung cancer. European J Cancer 4: 129, 1968.
Samuels, M., Leary, W., and Howe, C. Procarbazine (NSC 77213) in the treatment of advanced bronchogenic carcinoma. Cancer Chemother Rep 53: 135, 1969.
Stolinsky, D., Solomon, J., Pugh, R., et al. Procarbazine HCL in Hodgkin’s disease, reticulum-cell sarcoma and lymphosarcoma. Proc Amer Assoc Cancer Res 10: 88 (#350), 1969.
Flatow, F., Ultmann, J., Hyman, G., et al. Treatment of advanced Hodgkin’s disease with vinblastine (NSC 49842) or procarbazine (NSC 77213). Cancer Chemother Rep 53: 39, 1969.
Bonadonna, G., Monfardini, S., and Oldini, C. Comparative effects of vinblastine and procarbazine in advanced Hodgkin’s disease. Europ J Cancer 5: 393, 1969.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1970 IFI/Plenum · New York-Washington-London
About this chapter
Cite this chapter
Livingston, R.B., Carter, S.K. (1970). Procarbazine. In: Single Agents in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1378-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1378-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1380-9
Online ISBN: 978-1-4684-1378-6
eBook Packages: Springer Book Archive